Mar 25, 2021

ADT Security Australia launches IoT service for elderly care

elderly care
home care
IoT
remote patient monitoring
Leila Hawkins
2 min
ADT Security Australia launches IoT service for elderly care
ADT Security and Essence SmartCare launch IoT solution for elderly care in Australia...

Home security firm ADT Security Australia is set to deploy an IoT healthcare solution to enhance its offering for elderly people to live independent lives. 

[email protected], a telecare service from IoT platform developer Essence SmartCare, is a health monitoring solution that includes advanced fall detection and emergency alerting.

ADT Security Australia is owned by Johnson Controls, a building technology and software company that operates in over 150 countries. Although the company does not traditionally provide monitoring services for the elderly, this announcement comes amid the expected rapid growth of Australia’s aging population over the next 30 years.

HSC Technology Group have helped facilitate the partnership, which will enable ADT to provide new assistive services through Essence’s [email protected] solution under the banner of ADT Home Assure. 

[email protected] is a suite of products, providing health monitoring solutions that leverage a variety of advanced technologies including AI, to ensure the safety of seniors. The platform enables continuous monitoring of daily activities as well as voice-activated alerts so that caregivers and emergency services providers can communicate in real time. 

Part of the Essence Group, Essence SmartCare was founded in 2014, and develops platforms that enable smart preventive care and emergency response for market-leading healthcare and senior care providers. 

“We are honoured to be joining forces with ADT Security Australia, one of the largest security and safety solutions providers, to enable them to provide the best care and protection to Australian seniors,” said Barak Katz, General Manager for Essence SmartCare. 

"Our unified telehealth and care platform enables monitoring at any level and through any type of caring device for a wide range of health conditions, both at home or on-the-go – all through one connected [email protected] smart platform.” 

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article